Double maintains 1 strategies that include CHRS - Coherus Oncology, Inc.
Current Value
$0.731 Year Return
Current Value
$0.731 Year Return
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| PBE | 39.04% | $223.86M | 0.58% |
| ARKG | 38.60% | $1.02B | 0.75% |
| XBI | 38.56% | $4.84B | 0.35% |
| IBB | 37.72% | $5.28B | 0.45% |
| IWC | 36.59% | $817.74M | 0.6% |
| VBK | 36.47% | $18.99B | 0.07% |
| GNOM | 36.46% | $44.38M | 0.5% |
| IWO | 36.21% | $11.53B | 0.24% |
| ESPO | 35.47% | $388.91M | 0.56% |
| PINK | 35.45% | $129.96M | 0.5% |
| QQQJ | 35.22% | $618.04M | 0.15% |
| XMHQ | 35.10% | $4.97B | 0.25% |
| IBUY | 35.06% | $150.79M | 0.65% |
| KJAN | 34.93% | $287.49M | 0.79% |
| FBT | 34.66% | $1.01B | 0.54% |
| PTH | 34.61% | $100.70M | 0.6% |
| VFLO | 34.60% | $4.30B | 0.39% |
| KOMP | 34.47% | $2.28B | 0.2% |
| KJUL | 34.44% | $119.28M | 0.79% |
| VXF | 34.33% | $22.28B | 0.05% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -29.05% | $165.58M | 0.85% |
| BTAL | -28.64% | $295.67M | 1.43% |
| TAIL | -23.52% | $99.49M | 0.59% |
| XONE | -18.23% | $585.85M | 0.03% |
| IVOL | -14.33% | $348.25M | 1.02% |
| XHLF | -14.04% | $1.73B | 0.03% |
| SPTS | -13.15% | $5.77B | 0.03% |
| IBMN | -11.31% | $446.95M | 0.18% |
| TBLL | -10.30% | $2.13B | 0.08% |
| ULST | -9.84% | $658.54M | 0.2% |
| UTWO | -9.46% | $379.27M | 0.15% |
| VGSH | -8.58% | $22.77B | 0.03% |
| IBTG | -8.35% | $1.92B | 0.07% |
| FXY | -8.10% | $820.31M | 0.4% |
| CARY | -7.87% | $347.36M | 0.8% |
| IGOV | -7.22% | $1.21B | 0.35% |
| IBTH | -7.21% | $1.60B | 0.07% |
| BILS | -7.05% | $3.83B | 0.1356% |
| GBIL | -7.05% | $6.37B | 0.12% |
| NEAR | -6.71% | $3.34B | 0.25% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| SCHJ | 0.04% | $527.81M | 0.03% |
| TBIL | -0.06% | $5.83B | 0.15% |
| ISTB | 0.06% | $4.45B | 0.06% |
| DFNM | 0.10% | $1.57B | 0.17% |
| MEAR | -0.12% | $1.13B | 0.25% |
| JMST | 0.19% | $4.06B | 0.18% |
| HYMB | 0.22% | $2.62B | 0.35% |
| FLGV | -0.23% | $1.01B | 0.09% |
| SCHP | -0.24% | $12.99B | 0.03% |
| STOT | -0.33% | $253.88M | 0.45% |
| IBTM | -0.35% | $315.47M | 0.07% |
| UTEN | 0.36% | $209.27M | 0.15% |
| PULS | 0.37% | $11.70B | 0.15% |
| USFR | -0.37% | $18.59B | 0.15% |
| IBDR | -0.46% | $3.34B | 0.1% |
| BILZ | -0.50% | $827.73M | 0.14% |
| SCHR | -0.53% | $11.10B | 0.03% |
| IBTO | -0.54% | $351.41M | 0.07% |
| IBMR | -0.56% | $255.40M | 0.18% |
| IEF | 0.56% | $34.86B | 0.15% |
Yahoo
Krystal Biotech (KRYS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Yahoo
We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Steve Wagner’s Substack. In this article, we will summarize the bulls’ thesis on CHRS. Coherus BioSciences, Inc. (CHRS)’s share was trading at $0.77 as of 30th May. CHRS’s trailing P/E was 1.77 according to Yahoo Finance. Coherus BioSciences (CHRS), long overlooked by Wall Street, is […]
Yahoo
REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name change today to better align with its exclusive focus on proprietary innovative immuno-oncology medicines. “The field of cancer immunotherapy has been reinvigorated by the promise and power of combination therapies. Coherus Oncology has the expertise and pipeline to become a sign
Finnhub
Coherus BioSciences Inc: * COHERUS COMPLETES STRATEGIC TRANSFORMATION TO COHERUSONCOLOGY,FOCUSING EXCLUSIVELY ON INNOVATIVE CANCER THERAPEUTICSSource text:Further company coverage: ...
Finnhub
Coherus BioSciences, Inc. announced a clinical collaboration with STORM Therapeutics Ltd. to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI , a next-generation PD-1 inhibitor, in a...
Yahoo
– First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor –REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. (“STORM”) to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor, in a Phase 1b/2 study for the treatment o
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| WSM | 48.26% | $20.81B | +21.05% | 1.38% |
| W | 38.37% | $6.67B | +0.87% | 0.00% |
| XENE | 37.65% | $2.46B | -12.23% | 0.00% |
| KEYS | 36.23% | $28.31B | +20.54% | 0.00% |
| DLB | 35.87% | $7.26B | -5.95% | 1.71% |
| RGEN | 35.68% | $7.10B | +5.24% | 0.00% |
| ETSY | 34.99% | $5.36B | -11.84% | 0.00% |
| TREX | 34.35% | $6.18B | -20.54% | 0.00% |
| AZTA | 34.26% | $1.45B | -38.37% | 0.00% |
| VECO | 34.21% | $1.24B | -56.16% | 0.00% |
| RXRX | 34.20% | $2.09B | -28.35% | 0.00% |
| ZG | 33.52% | $16.77B | +59.78% | 0.00% |
| DNA | 33.52% | $630.84M | -18.04% | 0.00% |
| Z | 33.43% | $17.26B | +59.49% | 0.00% |
| SITE | 33.34% | $5.66B | +8.32% | 0.00% |
| BLFS | 33.15% | $1.03B | +7.07% | 0.00% |
| TECH | 33.13% | $8.16B | -26.90% | 0.62% |
| QTWO | 33.08% | $5.77B | +52.10% | 0.00% |
| MKSI | 32.92% | $6.76B | -24.09% | 0.87% |
| BKE | 32.89% | $2.41B | +36.60% | 2.99% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CBOE | -14.92% | $24.29B | +35.36% | 1.09% |
| VSTA | -11.55% | $341.66M | +42.00% | 0.00% |
| CME | -11.42% | $99.25B | +39.75% | 3.87% |
| VSA | -11.29% | $8.76M | -18.25% | 0.00% |
| KR | -10.00% | $47.17B | +41.48% | 1.81% |
| DUK | -9.74% | $92.39B | +19.10% | 3.55% |
| T | -8.94% | $207.81B | +53.45% | 3.83% |
| EXC | -7.79% | $43.82B | +25.72% | 3.63% |
| ED | -7.63% | $36.31B | +13.27% | 3.35% |
| AEP | -6.78% | $55.76B | +19.14% | 3.55% |
| TIMB | -6.16% | $9.79B | +45.56% | 2.02% |
| IMNN | -6.12% | $15.87M | -37.00% | 0.00% |
| VIV | -6.03% | $18.52B | +46.63% | 0.67% |
| VZ | -5.93% | $184.17B | +6.28% | 6.15% |
| MO | -5.90% | $97.93B | +26.25% | 6.95% |
| HCI | -5.81% | $1.69B | +57.98% | 1.12% |
| UVE | -5.55% | $771.45M | +50.73% | 2.37% |
| AEE | -5.51% | $26.67B | +34.81% | 2.88% |
| PHYS.U | -5.48% | - | - | 0.00% |
| IRWD | -5.45% | $113.65M | -88.71% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| O | -0.04% | $52.20B | +10.24% | 5.99% |
| ACI | 0.04% | $12.20B | +8.96% | 2.48% |
| CARM | 0.11% | $16.92M | -71.88% | 0.00% |
| LUMN | -0.12% | $4.63B | +321.50% | 0.00% |
| UGP | 0.16% | $3.56B | -13.58% | 3.76% |
| LHX | 0.17% | $47.14B | +12.78% | 1.89% |
| EZPW | 0.20% | $757.54M | +33.30% | 0.00% |
| CLX | 0.27% | $15.23B | -7.50% | 3.92% |
| PRMB | 0.28% | $11.13B | +44.89% | 1.26% |
| SAFT | -0.32% | $1.18B | +5.51% | 4.53% |
| CB | -0.33% | $116.05B | +13.31% | 1.30% |
| D | 0.33% | $49.16B | +18.77% | 4.67% |
| PCRX | 0.33% | $1.08B | +2.24% | 0.00% |
| TRV | -0.34% | $60.49B | +31.10% | 1.62% |
| DOGZ | -0.35% | $162.32M | -27.35% | 0.00% |
| BTG | 0.35% | $4.77B | +33.70% | 3.26% |
| MGPI | 0.38% | $680.27M | -56.20% | 1.49% |
| DG | 0.38% | $25.37B | -10.94% | 2.05% |
| PPC | -0.39% | $10.79B | +32.45% | 0.00% |
| RNR | -0.40% | $11.88B | +14.63% | 0.66% |
